Global Search

Hide Filters

Showing 2040 results

Press release / Jul 23, 2018

Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke

Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
Press release / Jan 24, 2018

Novartis erzielt 2017 eine gute operative Performance sowie wegweisende Innovationen und ist gut gerüstet für die nächste Wachstumsphase

Der Umsatz steigt im Geschäftsjahr um 2% (kWk, +1% USD), wobei die starke Performance unserer Wachstumstreiber, wie Cosentyx und Entresto, die Einbussen durch Generika bei Glivec/Gleevec mehr als…
Press release / Dec 02, 2019

Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms

With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in…
Press release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary…
Ad hoc release / Oct 08, 2019

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
Press release / Jun 03, 2019

Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (…
Press release / Jul 01, 2019

Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies

Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures …
Ad hoc release / Jan 29, 2021

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is…
Press release / Sep 21, 2020

Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score – confirming substantial benefit for premenopausal women with HR+/HER2- advanced…
Press release / Dec 08, 2020

Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial

At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…